LABP
Income statement / Annual
Last year (2023), Landos Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Landos Biopharma, Inc.'s net income was -$21.94 M.
See Landos Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$18.00 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$577,000.00
|
$196,000.00
|
$137,000.00
|
$103,000.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$577,000.00
|
$17.80 M
|
-$137,000.00
|
-$103,000.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0.99
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.00 M
|
$25.68 M
|
$41.56 M
|
$25.34 M
|
$11.81 M
|
$6.80 M
|
| General & Administrative Expenses |
$10.73 M
|
$14.88 M
|
$15.25 M
|
$5.34 M
|
$1.48 M
|
$1.14 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.73 M
|
$14.88 M
|
$15.25 M
|
$5.34 M
|
$1.48 M
|
$1.14 M
|
| Other Expenses |
$0.00
|
$1.29 M
|
$394,000.00
|
$0.00
|
$160,000.00
|
$2.01 M
|
| Operating Expenses |
$22.73 M
|
$40.56 M
|
$56.82 M
|
$30.68 M
|
$13.29 M
|
$7.94 M
|
| Cost And Expenses |
$22.73 M
|
$40.56 M
|
$56.82 M
|
$30.68 M
|
$13.29 M
|
$7.94 M
|
| Interest Income |
$0.00
|
$0.00
|
$412,000.00
|
$455,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$304,000.00
|
$4,000.00
|
| Depreciation & Amortization |
$44,000.00
|
$577,000.00
|
$196,000.00
|
$592,000.00
|
$263,000.00
|
$80,000.00
|
| EBITDA |
-$22.73 M |
-$40.56 M |
-$38.82 M |
-$30.08 M |
-$13.03 M |
-$5.85 M |
| EBITDA Ratio |
0
|
0
|
-2.16
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
-2.16
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$792,000.00
|
$1.29 M
|
$394,000.00
|
$532,000.00
|
-$177,000.00
|
$1.90 M
|
| Income Before Tax |
-$21.94 M
|
-$39.28 M
|
-$38.42 M
|
-$30.14 M
|
-$13.47 M
|
-$6.04 M
|
| Income Before Tax Ratio |
0
|
0
|
-2.13
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$1.29 M
|
-$196,000.00
|
$0.00
|
$464,000.00
|
$1.90 M
|
| Net Income |
-$21.94 M
|
-$37.99 M
|
-$38.23 M
|
-$30.14 M
|
-$13.93 M
|
-$6.04 M
|
| Net Income Ratio |
0
|
0
|
-2.12
|
0
|
0
|
0
|
| EPS |
-3.5 |
-9.44 |
-9.5 |
-7.51 |
-3.47 |
-2.62 |
| EPS Diluted |
-3.5 |
-9.44 |
-9.5 |
-7.51 |
-3.47 |
-2.62 |
| Weighted Average Shares Out |
$6.28 M
|
$4.03 M
|
$4.03 M
|
$4.01 M
|
$4.01 M
|
$2.31 M
|
| Weighted Average Shares Out Diluted |
$6.28 M
|
$4.03 M
|
$4.03 M
|
$4.01 M
|
$4.01 M
|
$2.31 M
|
| Link |
|
|
|
|
|
|
